Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05617131
Other study ID # 7599
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2020
Est. completion date December 31, 2023

Study information

Verified date December 2023
Source University Hospital, Strasbourg, France
Contact Natacha ENTZ-WERLE, MD, PhD
Phone 33 3 88 12 83 89
Email natacha.entz-werle@chru-strasbourg.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

About 2000 cancers/year in France are diagnosed in Adolescents and Young Adults (15-25 years old, AYA). The cancer plans and the INCA recommend support during and after cancer, taking into account both medical and psychosocial specificities related to age (supportive care, school learning/training and professional integration, fertility preservation, therapeutic education, addictology, sexology...). The care offered is often heterogeneous for these AYAs in transition between the pediatric and adult worlds. They may be cared for either in pediatric oncology units or in adult structures. In this context, an AYA team has been developed in the Strasbourg center, led by a Nurse Coordinator (IDEC), social workers, psychologists and doctors. Thus, the young patients and their relatives are accompanied by professionals during their therapeutic care. In spite of this global care and closer to the patient, it is still necessary to find connected health tools for these AYA.


Description:

In this context, the Strasbourg team has initiated the development of a digital application compatible for any cell phone OnKO-Tips &Tricks meeting these criteria of necessity. The application is currently in its final phase and requires validation by patients through a feasibility study that will last 6 months. Thus, all patients currently followed or newly diagnosed with liquid or solid cancer and aged between 15 and 25 years old will be included and will have the opportunity to test the application, its practicality as well as its current use and in particular its expected benefits for an optimization of our ETP program.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 31, 2023
Est. primary completion date December 2023
Accepts healthy volunteers
Gender All
Age group 15 Years to 25 Years
Eligibility Inclusion criteria: - Subject whose age is = 15 years and = 25 years - Subject diagnosed at the Strasbourg center (HUS and ICANS) with solid or liquid cancer - Subject followed in the Strasbourg center (HUS and ICANS) - Subject (or his/her legal representatives) having given his/her (their) agreement to participate in the evaluation survey of the OnKO-TnT digital application - Subject agreeing to complete all satisfaction questionnaires - The subject understands, speaks and writes French fluently - Subject having a cell phone capable of downloading the application (developed for any type of cell phone) Criteria for non-inclusion : - Opposition of the subject (or the holders of parental authority) to participate in the satisfaction survey - Subject under legal protection - Subject under guardianship or curatorship

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Service Pédiatrie Onco-hématologie - Pédiatrie III - CHU de Strasbourg - France Strasbourg

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Collection of the global score of the MAUQ questionnaire (item 1 to 21), filled in by the patients after 6 months of use of the OnKO-TnT application MAUQ questionnaire of 21 items with a score ranging from 1 to 7. Score 7 means a better result after 6 months of use of the OnKO-TnT application
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients